Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blake S Moses

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Oncotarget|March 26, 2016
BCL6 modulation of acute lymphoblastic leukemia response to chemotherapyWilliam L Slone, Blake S Moses, Ian Hare, et al.
Molecular Cancer Research : MCR|July 1, 2016
Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic LeukemiaBlake S Moses, Rebecca Evans, William L Slone, et al.
Plos One|October 22, 2015
Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic LeukemiaAllison Bruce, Rebecca Evans, Ryan Mezan, et al.
Journal of Visualized Experiments : Jove|February 19, 2016
Modeling Chemotherapy Resistant Leukemia In VitroWilliam L Slone, Blake S Moses, Rebecca Evans, et al.
Frontiers in Oncology|February 7, 2022
A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable PharmacologyAmanda B Kagan, Blake S Moses, Bryan T Mott, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2023
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivativeAmanda B Kagan, Blake S Moses, Rena Lapidus, et al.
Experimental Hematology|September 27, 2015
Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotypeBlake S Moses, William L Slone, Patrick Thomas, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Leukemia|November 17, 2020
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemiaAshkan Emadi, Bandish Kapadia, Dominique Bollino, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Oncotarget|March 26, 2016
BCL6 modulation of acute lymphoblastic leukemia response to chemotherapyWilliam L Slone, Blake S Moses, Ian Hare, et al.
Molecular Cancer Research : MCR|July 1, 2016
Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic LeukemiaBlake S Moses, Rebecca Evans, William L Slone, et al.
Plos One|October 22, 2015
Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic LeukemiaAllison Bruce, Rebecca Evans, Ryan Mezan, et al.
Journal of Visualized Experiments : Jove|February 19, 2016
Modeling Chemotherapy Resistant Leukemia In VitroWilliam L Slone, Blake S Moses, Rebecca Evans, et al.
Frontiers in Oncology|February 7, 2022
A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable PharmacologyAmanda B Kagan, Blake S Moses, Bryan T Mott, et al.
Cancer Chemotherapy and Pharmacology|May 30, 2023
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivativeAmanda B Kagan, Blake S Moses, Rena Lapidus, et al.
Experimental Hematology|September 27, 2015
Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotypeBlake S Moses, William L Slone, Patrick Thomas, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Leukemia|November 17, 2020
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemiaAshkan Emadi, Bandish Kapadia, Dominique Bollino, et al.
Pageof 1